Consistently, in two additional AML cell lines, OCI-AML3 and MOLM-13, we observed strong co-enrichment of both β-catenin and IRF7 on the promoters of key type I IFN genes — STAT1, IFIH1 and STAT2 — only in cells treated with combo (Extended Data Fig. 4d–g). The gene discussed is RUNX2; the disease is acute myeloid leukemia.